Amgen Inc. (AMGN), a prominent Biotech firm, has been gaining investor attention as it deals with market uncertainties. While its stock has been fluctuating, with a 10% drop over three months, it maintains a strong institutional ownership of 81%. Several investment groups and asset managers such as BRITISH COLUMBIA INVESTMENT MANAGEMENT, Blue Fin Capital and Twinbeech Capital LP have either purchased or increased their holdings. Exceptionally, Siemens Fonds Invest GmbH and Zurich Insurance Group Ltd FI opted to trim their positions.
Despite market exclusivity loss for some key drugs, Amgen is seen as a strong value stock for its solid financial performance reflected in its Q1 2025 earnings result and projections. Institutional investors are anticipating the profitability of AMGN's obesity drug currently in production, as AMGN faces a $407 Million verdict over antitrust violations.
Several asset management companies have been enlarging their positions in Amgen, while a few reduced or sold their stock. Despite the multifaceted challenges and mixed expectations, Amgen remains a popular choice amid the domestic manufacturing boom, providing an optimistic bull case for investors.
Amgen AMGN News Analytics from Tue, 07 Jan 2025 08:00:00 GMT to Sat, 24 May 2025 14:00:11 GMT -
Rating 4
- Innovation 3
- Information 5
- Rumor -3
